Health ❯ Healthcare ❯ Oncology

Breast Cancer

HER2-positive Breast Cancer Clinical Trials Triple-Negative Breast Cancer Treatment Options Diagnosis Adverse Effects Diagnosis and Treatment Metastatic Breast Cancer HER2-positive Metastatic Breast Cancer Antibody-Drug Conjugates Camizestrant Toxicity Management Risk Factors Treatment Advances Patient Care Hormone Receptor Positive Breast Cancer Treatment Strategies Prevention Patient Experiences Surgical Treatment Public Health Campaigns Therapeutic Advances Patient Management Recurrence Risk Recurrence Prevention Therapeutic Strategies Treatment Monitoring Early Stage Breast Cancer Lipid Metabolism Precision Medicine Warburg Effect Metabolic Reprogramming Glutamine Metabolism Trastuzumab Pamirtecan Triple-Negative Breast Cancer (TNBC) Antibody Drug Conjugates International Congress ESR1-Mutated Breast Cancer Treatment Approvals Treatment Protocols Micropigmentation Efficacy and Safety PI3K/mTOR Inhibitors Treatment Regimens BRCA1 Gene Prevention Strategies Awareness Campaigns Datroway Patient Education Genetic Testing Awareness and Prevention Sentinel Lymph Node Biopsy Public Health Awareness Community Engagement Artificial Intelligence HER2-Positive Breast Cancer Treatment Research Treatment Efficacy Resistance Mechanisms Hormone Receptor-Positive Breast Cancer Immunotherapy Advanced Breast Cancer Hormone Therapy Hormonal Receptors HER2-positive Treatment Liquid Biopsy Screening Techniques ESR1 Mutations Mastectomy Radical Mastectomy Trastuzumab Entansina Muscle Mass Management Anti-hormonal Therapy HER2-Directed Therapies Targeted Therapy Access to Care Chemotherapy Estrogen Receptor Mutations PIK3CA Mutation ADCs in Breast Cancer Hormonal Therapy Cancer Treatment Centers Advanced ER-Positive Breast Cancer Screening Programs Survivorship Issues Breast Cancer Screening Clinical Research

Athira Pharma Secures Exclusive Lasofoxifene Rights, Raises $90 Million to Advance Phase 3 Breast Cancer Program

Fresh funding is slated to carry the late-stage study toward a mid-2027 readout pending an expected closing next week.

FDA Clears Enhertu-Perjeta Combo for First-Line HER2-Positive Metastatic Breast Cancer

Trial Finds Some Early Breast Cancer Patients Can Skip Sentinel Node Biopsy Without Harming 5-Year Control

Phase II Trial Finds 24 Gy Preoperative Radiation With Pembrolizumab Boosts T‑Cell Infiltration in HR+/HER2− Breast Cancer

Tucatinib Added to First-Line HER2 Maintenance Prolongs Progression-Free Survival in Phase 3 Trial

Sacituzumab Govitecan Gains First-Line Ground in TNBC, Falls Short in Early HR+/HER2− Use

Roche’s Giredestrant Cuts Early Breast Cancer Recurrence 30% in Phase III Trial

Olema Soars on Roche SERD Win, Then Slips on Planned Stock Offering

FDA Approves Poherdy as First Interchangeable Biosimilar to Perjeta for HER2-Positive Breast Cancer

ASCENT-03 Finds Sacituzumab Govitecan Extends PFS Over Chemotherapy in First-Line PD-L1–Negative TNBC

Kisqali Cuts Recurrence in 5-Year NATALEE Results for High-Risk Early HR+/HER2- Breast Cancer

Phase 3 Trial Finds Tukysa Improves PFS in First-Line Maintenance for HER2-Positive Metastatic Breast Cancer

Datroway Extends Survival Over Chemotherapy in First-Line TNBC Ineligible for Immunotherapy

FDA Grants Priority Review for Enhertu Plus Pertuzumab in First-Line HER2-Positive Metastatic Breast Cancer

Preclinical PET Tracer Enables Same-Day Imaging of Nectin-4 in Breast and Bladder Cancers

Paclitaxel Reengineered Into Self-Assembling Nanovesicle Shows Strong Preclinical Gains

Everolimus Plus Carboplatin Delays Progression in Advanced Triple-Negative Breast Cancer, Phase 2 Study Shows

Study Urges Geriatric Assessments for Growing Population of Older Breast Cancer Survivors

Arvinas’ Vepdegestrant Delays Breast Cancer Progression Longer Than Faslodex

Oral HIV Drug Lamivudine Improves Vision in Diabetic Macular Edema Trial